🔗 Share this article

As the US proceeds with unprecedented changes to its immunization guidelines, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 shots in the global health crisis and has concentrated on potential deaths following Covid vaccination in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Schedule

Health officials planned to announce major changes to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, it is understood – a substantial departure that would put the US out of alignment with much of the global community with insufficient data for public health gain. This reveal has been pushed back until the new year.

Instead of the director of the vaccine center, Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to run the center this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a strengthened alliance between the drug and biologics centers as Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric shot schedules in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

To date statements, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has little discernible background in pharmaceutical research, regulation or management, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Previous heads of the center would “grasp laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

This division has an enormous workload at the agency, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the generic drug division clears a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one have to be looked after,” Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative element to the position, which supervises in excess of 5,000 staff members. “It’s a huge management job, if you execute it properly,” she added.

Agency Reaction and Controversial Initiatives

In response to questions about Dr. Høeg's credentials and whether this assignment represents more teamwork among regulatory chiefs on immunizations, a representative said that the “concerns rely on flawed premises”.

“Her experience matches the responsibilities of her role,” the official said, pointing to the time Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a disputed expedited medication authorization process that apparently troubled her former heads. “How are these therapies being chosen for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards laxer rules of all drugs, except for vaccines.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, track record, some experts have noted. She released a research paper using non-validated public submissions to assess the incidence of heart inflammation after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new administration encompassed changing regulations for novel immunizations and ending “optional” immunizations, she stated following the vote on a online show. At the agency, Høeg has allegedly floated the idea of excluding teenage boys from receiving Covid vaccines.

“She’s an all-around ideologue who commences with her conclusions and tailors the evidence to retrofit the evidence in a very disingenuous, fraudulent way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|